Drugs in Dev. Neurology
Discovery
China 
X-Chem and Sironax Begin Neurodegenerative Disease Drug Discovery Research Partnership
Details : X-Chem will screen its unique DNA-encoded libraries against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into transformational medicines for degenerative disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 05, 2023
NeuShen Therapeutics Closes Pre-A Financing with ~$20M
Details : The successful completion of this fundraising is a testimony to team's ability to accomplish CNS drug development and jump starts the discovery engine to build a pipeline with AAV-based gene therapy and small molecule programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 29, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : Mitsubishi Tanabe Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : During the three-year collaboration, multiple undisclosed targets (including undruggable targets) were screened against HitGen’s proprietary DNA encoded chemical libraries (DELs). The majority of the targets have resulted in confirmed novel potent hits...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 25, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : Mitsubishi Tanabe Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
